About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

Quality assessment of english and spanish oral cancer websites

Source: AMIA Annu Symp Proc, January 1, 2007; 987 Author: JY Irwin, T Wali, S Fernando, and T Schleyer Authors' affiliation: University of Pittsburgh Based on the morbidity and mortality due to oral cancer, it is essential that oral cancer information available on the Internet be usable, organized and credible. We evaluated the information quality of 24 English-language and 25 Spanish-language oral cancer websites. English-language sites scored 74.7 out of 100 points on the Information Quality Tool scale, while Spanish-language sites scored 48.8. Developers of oral cancer websites should improve the design, organization and credibility of the information presented.

2008-08-19T07:54:50-07:00August, 2008|Oral Cancer News|
Read More

Tumour therapy drug to be reviewed

Source: PharmacyEurope (www.pharmacyeurope.net) Author: staff The European Medicines Agency (EMEA) is to review a drug targeted at the treatment of recurrent cancer of the head and neck. Advexin is designed to restore the tumour suppressing gene p53 that is blocked in the majority of tumours. If approved, it will be the first gene therapy product approved for use in Europe. "This acceptance of the Advexin Marketing Authorisation Application (MAA) by the EMEA marks an historic point in the growth of personalised medicine, and the treatment of head and neck cancer," said Max Talbott, senior vice president of worldwide commercial development at the drug's developer, Introgen Therapeutics. "This action by the EMEA underscores the rapidly increasing importance of biomarkers, in the development and regulatory approval processes for targeted therapeutics. We look forward to working with the EMEA during the Advexin review process, which we hope will lead to the first gene therapy product in Europe." The MAA follows a phase III study of Advexin in patients with recurrent, refractory squamous cell carcinoma of the head and neck. It successfully achieved its goal, which was survival or tumour response in patients

2008-08-19T05:39:23-07:00August, 2008|Oral Cancer News|
Read More

Paltrow spearheads cancer campaign

Source: ShanghaiDaily.com Author: Marc Karimzadeh Raising money to fight cancer is very close to Gwyneth Paltrow's heart - which is why she was happy to become the sixth Oscar-winning actress to champion a major cause, writes Marc Karimzadeh. Gwyneth Paltrow is painfully familiar with cancer. Her father, Bruce, died of complications from the disease in 2002, and the actress says many of her friends have been diagnosed with cancer. Some are still fighting it. So Paltrow jumped at the chance when the Entertainment Industry Foundation approached her to become the 2008 ambassador for its annual Key to the Cure campaign in conjunction with Saks Fifth Avenue. "If there is anything I can do to help raise money, especially with a charity like this, I will," Paltrow said. "I read about the charity and how aggressively they are trying to find a cure, not only for women's cancers but also for other cancers. They support people who are coming up with innovative ideas to cure cancer." Paltrow added that the initiative will also donate money to the Bruce Paltrow Oral Cancer Fund. She is the sixth Oscar-winning actress to become the ambassador to the KTTC program. This year, Karl Lagerfeld created a special T-shirt to benefit the initiative. The 2008 effort also marks a milestone for Saks Fifth Avenue. It's the 10th anniversary of Saks' charity shopping event, which, in conjunction with its vendors and partners, has raised more than US$28 million for cancer institutions. Saks first partnered with the Council [...]

2008-08-17T17:10:46-07:00August, 2008|Oral Cancer News|
Read More

Helping Tumor Cells Not To Stick To The Wound During Surgical Removal

Source: Science Daily (www.sciencedaily.com) Author: staff Sometimes during surgery to remove a tumor, cells become detached from the bulk of the tumor. In a small number of cases, these tumor cells stick to cells at the site of the surgical wound and go on to form a secondary tumor, having an enormous negative impact on the survival and quality of life of the patient. New data, generated by Marc Basson and colleagues, at the John D. Dingell VA Medical Center and Wayne State University, Detroit, using a mouse model of surgery to remove a colon cancer tumor, suggest that perioperative treatment with a drug known as colchicine might decrease the incidence of tumor formation at the site of the surgical wound. When colon cancer tumor cells are exposed to high pressure they exhibit an increased ability to stick to other cells. In the study, to mimic the conditions of surgery, the authors removed colon cancer cells from one mouse, exposed them to high pressure in vitro, and then transplanted them into a second mouse that they monitored for the development of tumors at the site of the surgical wound. The most important observation made was that if the mice from which the colon cancer cells came from were treated perioperatively with colchicine there was a dramatic decrease in the number of tumors that formed at the site of the surgical wound in the second mouse. As in vitro exposure of tumor cells from breast and head and neck cancers to [...]

2008-08-15T21:45:53-07:00August, 2008|Oral Cancer News|
Read More

Does Pretreatment Seropositivity to Human Papillomavirus Have Prognostic Significance for Head and Neck Cancers?

Source: Cancer Epidemiology Biomarkers & Prevention 17, 2087-2096, August 1, 2008 Authors: Elaine M. Smith et al. Background: Human papillomavirus (HPV) is a risk factor for head and neck cancers (HNC), yet HPV-associated tumors have better prognosis than HPV-negative tumors. Methods: We evaluated whether pretreatment presence of antibodies to HPV capsids [virus-like particles (VLP)] or to HPV-16 oncoproteins E6 and E7 was a predictor of HPV-positive HNC and clinical outcomes. Sera from 156 HNC patients were tested for antibodies to HPV-16–derived antigens using ELISA. HPV-16 in tumors was evaluated by PCR and DNA sequencing. Results: HPV-16 antibodies were found in 33% with HPV-16 VLP, 21% with HPV-16 E6, and 21% with E7. HPV-16 was detected in 26% of tumors. There was a strong correlation between detection of HPV-16 tumor DNA and antibodies to HPV-16 E6 or E7 ( = 0.7) but not to HPV-16 VLP ( = 0.4). Multivariate analyses showed significantly better disease-specific survival in seropositive HPV-16 VLP [hazard ratio (HR), 0.4; 95% confidence interval (95% CI), 0.1-0.9], HPV-16 E6 (HR, 0.1; 95% CI, 0.02-0.5), and HPV-16 E7 (HR, 0.3; 95% CI, 0.1-0.9) cases. Less disease recurrence occurred among those with antibodies to both E6 and E7 compared with those negative to both (P = 0.003). There was better disease-specific survival in patients who were E6 positive at baseline and remained positive at follow-up compared with individuals who were E6 negative at both time points (P = 0.03; = 0.9). Conclusions: The presence of antibodies to HPV-16 E6 and [...]

2008-08-15T21:40:30-07:00August, 2008|Oral Cancer News|
Read More

Laser Treatment Zaps Oral Cancer

Source: Jacksonville News (www.news4jax.com) Author: staff This year, more than 34,000 people in the United States will be diagnosed with oral cancer -- a cancer that has a higher death rate than cervical cancer, Hodgkin's lymphoma, or skin cancer. Survival rates are not improving; but now, a new treatment may give doctors a way to stop oral cancers before they start. They're often detected in a routine dental or doctor's exam … red or white lesions called leukoplakia that can turn into serious, even deadly oral cancers. "I do happen to know people that have died of this kind of cancer and so we watch it very closely," said Mike Hagerman, a former smoker and a two-time oral cancer survivor. Now, Hagerman's leukoplakia is back. This time, he's part of a study testing a new photodynamic laser treatment designed to eliminate precancerous cells. "When the laser fires onto the lesion, it emits light at a very specific frequency that causes oxygen radicals that destroy the lesion, make it go away," explained Stuart Wong, M.D., a medical oncologist at the Medical College of Wisconsin in Milwaukee. Tested on the hand or used in the mouth on actual lesions, researchers say the laser doesn’t hurt. It’s a preventive measure that doctor say could save lives. "There is some emerging data that the better we can kill off these early precancerous lesions, that that might translate later down the road many, many years to a decreasing in the development of cancers and that's [...]

2008-08-15T21:05:49-07:00August, 2008|Oral Cancer News|
Read More

Lifestyle risk factors for oral cancer

Source: Oral Oncol, July 30, 2008 Author: Stefano Petti The "style of life is the unique way in which individuals try to realize their fictional final goal and meet or avoid the three main tasks of life: work, community, love" (Alfred Adler, founder of the Individual Psychology). Lifestyle refers to the way individuals live their lives and how they handle problems and interpersonal relations. The lifestyle behaviours associated to oral cancer with convincing evidence are tobacco use, betel quid chewing, alcohol drinking, low fruit and vegetable consumption (the detrimental lifestyle is high fat and/or sugar intake, resulting in low fruit and/or vegetable intake). Worldwide, 25% of oral cancers are attributable to tobacco usage (smoking and/or chewing), 7-19% to alcohol drinking, 10-15% to micronutrient deficiency, more than 50% to betel quid chewing in areas of high chewing prevalence. Carcinogenicity is dose-dependent and magnified by multiple exposures. Conversely, low and single exposures do not significantly increase oral cancer risk. These behaviours have common characteristics: (i) they are widespread: one billion men, 250 million women smoke cigarettes, 600-1200 million people chew betel quid, two billion consume alcohol, unbalanced diet is common amongst developed and developing countries; (ii) they were already used by animals and human forerunners millions of years ago because they were essential to overcome conditions such as cold, hunger, famine; their use was seasonal and limited by low availability, in contrast with the pattern of consumption of the modern era, characterized by routine, heavy usage, for recreational activities and with multiple [...]

2008-08-15T17:22:46-07:00August, 2008|Oral Cancer News|
Read More

Current concepts in management of oral cancer – Surgery

Source: Oral Oncol, July 30, 2008 Authors: Jatin P Shah and Ziv Gil Oral cancer is the sixth most common cancer worldwide, with a high prevalence in South Asia. Tobacco and alcohol consumption remain the most dominant etiologic factors, however HPV has been recently implicated in oral cancer. Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers. The factors that affect choice of treatment are related to the tumor and the patient. Primary site, location, size, proximity to bone, and depth of infiltration are factors which influence a particular surgical approach. Tumors that approach or involve the mandible require specific understanding of the mechanism of bone involvement. This facilitates the employment of mandible sparing approaches such as marginal mandibulectomy and mandibulotomy. Reconstruction of major surgical defects in the oral cavity requires use of a free flap. The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity. The fibula free flap remains the choice for mandibular reconstruction. Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy. The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches [...]

2008-08-15T17:17:34-07:00August, 2008|Oral Cancer News|
Read More

Fight Against Cancer: Patient vs. Process

Why One Cancer Patient Is Fighting a Drug Company Working on a Cure Source: abcnews.go.com Author: John Donovan On this relatively good morning in the course of her mom's inoperable cancer, Jackie Loughman, of Indianapolis, knows some facts about pain that she wishes she didn't. "She is mostly in bed and in pain all the time, and, you know, it is hard to watch," Loughman said of her mother, Connie. But the fact really throwing Jackie and Connie is that there is a drug out there that has saved at least one pancreatic cancer patient — and Connie can't get it. Richard Jordan, a Colorado landscaper, was supposed to be dead by now, but he got into a trial for the drug TNFerade. His wife called it "a miracle." Jordan's oncologist, Dr. Raj J. Shah of the University of Colorado, said, "The remarkable thing of his story is that he went on to surgery — but more importantly, when they removed the mass, no cancer was left or seen. With pancreatic cancer, the complete response is really rare." Connie is disqualified from the TNFerade trial by her participation in an earlier trial for a different drug that she says made her sick. TNFerade is made in Maryland by a small firm called GenVec, which told Jackie and ABC News in a statement: "We are working aggressively to advance our product candidate, TNFerade, through the required clinical studies and regulatory review process. ... Unfortunately, this process makes it impossible for GenVec [...]

2008-08-14T17:35:58-07:00August, 2008|Oral Cancer News|
Read More

Evidence-Based Recommendations for Cancer Fatigue, Anorexia, Depression, and Dyspnea

Source: Journal of Clinical Oncology, Vol 26, No 23 (August 10), 2008: pp. 3886-3895 Authors: Sydney M. Dy et al. Purpose: The experience of patients with cancer often involves symptoms of fatigue, anorexia, depression, and dyspnea. Methods: We developed a set of standards through an iterative process of structured literature review and development and refinement of topic areas and standards and subjected recommendations to rating by a multidisciplinary expert panel. Results: For fatigue, providers should screen patients at the initial visit, for newly identified advanced cancer, and at chemotherapy visits; assess for depression and insomnia in newly identified fatigue; and follow up after treatment for fatigue or a secondary cause. For anorexia, providers should screen at the initial visit for cancer affecting the oropharynx or gastrointestinal tract or advanced cancer, evaluate for associated symptoms, treat underlying causes, provide nutritional counseling for patients undergoing treatment that may affect nutritional intake, and follow up patients given appetite stimulants. For depression, providers should screen newly diagnosed patients, those started on chemotherapy or radiotherapy, those with newly identified advanced disease, and those expressing a desire for hastened death; document a treatment plan in diagnosed patients; and follow up response after treatment. For general dyspnea, providers should evaluate for causes of new or worsening dyspnea, treat or symptomatically manage underlying causes, follow up to evaluate treatment effectiveness, and offer opioids in advanced cancer when other treatments are unsuccessful. For dyspnea and malignant pleural effusions, providers should offer thoracentesis, follow up after thoracentesis, and offer pleurodesis [...]

2008-08-14T17:21:09-07:00August, 2008|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top